Skip to main content
PMC home page
Postgraduate Medical Journal logoLink to Postgraduate Medical Journal
. 1985 Sep;61(719):779–783. doi: 10.1136/pgmj.61.719.779

Carbamazepine substitution in severe partial epilepsy: implication of autoinduction of metabolism.

G J Macphee, M J Brodie
PMCID: PMC2418387  PMID: 3932988

Abstract

Established partial seizures are often refractory to treatment and many patients receive polypharmacy. An attempt was made to improve seizure control with the substitution of carbamazepine (CBZ) for existing treatment in 7 consecutive unremitting cases of partial epilepsy referred by their physicians as 'intractable'. This produced a significant improvement in control of partial (P less than 0.02) and secondary generalized (P less than 0.01) seizures, with 5 patients experiencing a 50% or greater reduction in seizure frequency. A single patient suffered a generalized seizure during the period of changeover. In 3 cases auto-induction of CBZ metabolism resulted in temporary loss of seizure control which was restored by an increase in dose. A policy of planned substitution of CBZ in partial epilepsy previously regarded as intractable may be successful in selected patients. The possible deleterious effect of CBZ auto-induction should be anticipated.

Full text

PDF
782

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Callaghan N., O'Callaghan M., Duggan B., Feely M. Carbamazepine as a single drug in the treatment of epilepsy. A prospective study of serum levels and seizure control. J Neurol Neurosurg Psychiatry. 1978 Oct;41(10):907–912. doi: 10.1136/jnnp.41.10.907. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Cereghino J. J., Brock J. T., Van Meter J. C., Penry J. K., Smith L. D., White B. G. Carbamazepine for epilepsy. A controlled prospective evaluation. Neurology. 1974 May;24(5):401–410. doi: 10.1212/wnl.24.5.401. [DOI] [PubMed] [Google Scholar]
  3. Cereghino J. J., Brock J. T., Van Meter J. C., Penry J. K., Smith L. D., White B. G. The efficacy of carbamazepine combinations in epilepsy. Clin Pharmacol Ther. 1975 Dec;18(6):733–741. doi: 10.1002/cpt1975186733. [DOI] [PubMed] [Google Scholar]
  4. Davidson D. L. Anticonvulsant drugs. Br Med J (Clin Res Ed) 1983 Jun 25;286(6383):2043–2045. doi: 10.1136/bmj.286.6383.2043. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Eichelbaum M., Ekbom K., Bertilsson L., Ringberger V. A., Rane A. Plasma kinetics of carbamazepine and its epoxide metabolite in man after single and multiple doses. Eur J Clin Pharmacol. 1975 Jun 13;8(5):337–341. doi: 10.1007/BF00562659. [DOI] [PubMed] [Google Scholar]
  6. Fischbacher E. Effect of reduction of anticonvulsants on wellbeing. Br Med J (Clin Res Ed) 1982 Aug 7;285(6339):423–424. doi: 10.1136/bmj.285.6339.423. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Goodridge D. M., Shorvon S. D. Epileptic seizures in a population of 6000. I: Demography, diagnosis and classification, and role of the hospital services. Br Med J (Clin Res Ed) 1983 Sep 3;287(6393):641–644. doi: 10.1136/bmj.287.6393.641. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Kosteljanetz M., Christiansen J., Dam A. M., Hansen B. S., Lyon B. B., Pedersen H., Dam M. Carbamazepine vs phenytoin. A controlled clinical trial in focal motor and generalized epilepsy. Arch Neurol. 1979 Jan;36(1):22–24. doi: 10.1001/archneur.1979.00500370052010. [DOI] [PubMed] [Google Scholar]
  9. Lesser R. P., Pippenger C. E., Lüders H., Dinner D. S. High-dose monotherapy in treatment of intractable seizures. Neurology. 1984 Jun;34(6):707–711. doi: 10.1212/wnl.34.6.707. [DOI] [PubMed] [Google Scholar]
  10. Maheshwari M. C., Padmini R. Role of carbamazepine in reducing polypharmacy in epilepsy. Acta Neurol Scand. 1981 Jul;64(1):22–28. doi: 10.1111/j.1600-0404.1981.tb04382.x. [DOI] [PubMed] [Google Scholar]
  11. Ramsay R. E., Wilder B. J., Berger J. R., Bruni J. A double-blind study comparing carbamazepine with phenytoin as initial seizure therapy in adults. Neurology. 1983 Jul;33(7):904–910. doi: 10.1212/wnl.33.7.904. [DOI] [PubMed] [Google Scholar]
  12. Rapeport W. G., McInnes G. T., Thompson G. G., Forrest G., Park B. K., Brodie M. J. Hepatic enzyme induction and leucocyte delta-aminolaevulinic acid synthase activity: studies with carbamazepine. Br J Clin Pharmacol. 1983 Aug;16(2):133–137. doi: 10.1111/j.1365-2125.1983.tb04976.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Reynolds E. H. Chronic antiepileptic toxicity: a review. Epilepsia. 1975 Jun;16(2):319–352. doi: 10.1111/j.1528-1157.1975.tb06062.x. [DOI] [PubMed] [Google Scholar]
  14. Reynolds E. H., Elwes R. D., Shorvon S. D. Why does epilepsy become intractable? Prevention of chronic epilepsy. Lancet. 1983 Oct 22;2(8356):952–954. doi: 10.1016/s0140-6736(83)90462-2. [DOI] [PubMed] [Google Scholar]
  15. Reynolds E. H. Serum levels of anticonvulsant drugs. Interpretation and clinical value. Pharmacol Ther. 1980;8(2):217–235. doi: 10.1016/0163-7258(80)90047-9. [DOI] [PubMed] [Google Scholar]
  16. Reynolds E. H., Shorvon S. D., Galbraith A. W., Chadwick D., Dellaportas C. I., Vydelingum L. Phenytoin monotherapy for epilepsy: a long-term prospective study, assisted by serum level monitoring, in previously untreated patients. Epilepsia. 1981 Aug;22(4):475–488. doi: 10.1111/j.1528-1157.1981.tb06158.x. [DOI] [PubMed] [Google Scholar]
  17. Rimmer E. M., Richens A. Double-blind study of gamma-vinyl GABA in patients with refractory epilepsy. Lancet. 1984 Jan 28;1(8370):189–190. doi: 10.1016/s0140-6736(84)92112-3. [DOI] [PubMed] [Google Scholar]
  18. Rodin E. A., Rim C. S., Rennick P. M. The effects of carbamazepine on patients with psychomotor epilepsy: results of a double-blind study. Epilepsia. 1974 Dec;15(4):547–561. doi: 10.1111/j.1528-1157.1974.tb04028.x. [DOI] [PubMed] [Google Scholar]
  19. Shorvon S. D., Chadwick D., Galbraith A. W., Reynolds E. H. One drug for epilepsy. Br Med J. 1978 Feb 25;1(6111):474–476. doi: 10.1136/bmj.1.6111.474. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Shorvon S. D., Reynolds E. H. Reduction in polypharmacy for epilepsy. Br Med J. 1979 Oct 27;2(6197):1023–1025. doi: 10.1136/bmj.2.6197.1023. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Simonsen N., Olsen P. Z., Kühl V., Lund M., Wendelboe J. A comparative controlled study between carbamazepine and diphenylhydantoin in psychomotor epilepsy. Epilepsia. 1976 Jun;17(2):169–176. doi: 10.1111/j.1528-1157.1976.tb03394.x. [DOI] [PubMed] [Google Scholar]
  22. Thompson P. J., Trimble M. R. Anticonvulsant drugs and cognitive functions. Epilepsia. 1982 Oct;23(5):531–544. doi: 10.1111/j.1528-1157.1982.tb05439.x. [DOI] [PubMed] [Google Scholar]
  23. Troupin A. S., Ojemann L. M. Paradoxical intoxication--a complication of anticonvulsant administration. Epilepsia. 1975 Dec;16(5):753–758. doi: 10.1111/j.1528-1157.1975.tb04761.x. [DOI] [PubMed] [Google Scholar]
  24. Troupin A., Ojemann L. M., Halpern L., Dodrill C., Wilkus R., Friel P., Feigl P. Carbamazepine--a double-blind comparison with phenytoin. Neurology. 1977 Jun;27(6):511–519. doi: 10.1212/wnl.27.6.511. [DOI] [PubMed] [Google Scholar]

Articles from Postgraduate Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES